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The emerging possibilities of treating the inflammatory bowel diseases (IBD), 
Crohn's disease and ulcerative colitis, with biologics towards the end of the 1990's, 
tended to revolutionize the management of patients. The new biologics were, 
however, expensive, and it became essential to be able to monitor the clinical 
efficacy, the health economic burden, and the real-life effects of these medications. 
Therefore, in Denmark, it became mandatory to register information on treatment 
with biologics for IBD in a national quality database. 
At Aalborg University Hospital, a former population-based cohort database 
contained information on all IBD patients diagnosed and followed through 1978-
2002 in the North Denmark Region. By 2014, this database was no longer 
operational and there was only scarce updating of patients. The need for at new 
database with the ability to include updated information on diagnosis, phenotypes, 
disease course and treatment as well as patient reported outcomes became evident, in 
particular to provide clinicians with a continuously updated overview of treatments 
and effects, and optimally, this database should also be able to report to the national 
quality database for treatment with biologics and provide the basis for observational 
research and recruitment for trials. The PhD study deals with the establishment of 
such a database and the use of it. 
The solution became GASTROBIO, a web-based registry for clinical registration of 
patient characteristics and patient management - with associated touch screens, 
where patients register their symptoms before each consultation (being it with a 
physician or a nurse) and before every infusion of biologics. These touch screen 
registrations, which are validated quality of life and disease activity scores, as well 
as information on side effects, smoking habits, and weight, are immediately 
available for the doctors and nurses, enabling discussion of patient reports during the 
visit. All in all, the database gives the staff an overview of the patient's disease 
history, including disease extent, medications, endoscopies, laboratory data, family 
history, height, and weight together with these patient reported outcomes. Thus, 
GASTROBIO provides a tool for clinical management of patients, for extensive 
research possibilities (which are enhanced after all information from the previous 
database has been migrated to GASTROBIO), and the database is fully compatible 
with and delivers monthly data to the national quality registry for treatment with 
biologics, with no extra effort or double registering for the staff. 
During the establishment of GASTROBIO, three specific questions emerged: 1) Is it 
feasible to set up touch screens in the outpatient clinic?, 2) Can we assess real life 
use of the biological drug, infliximab, during the first 16 years post marketing?, and 
3) Are we able to use the database to identify eligible patients for the study of a 
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specific clinical question? This led to the three projects upon which the PhD is 
based. 
In the first study, we evaluated the validity of touch screens in the outpatient clinic 
(as opposed to paper questionnaires), showing good feasibility and optimization of 
data completeness. This led to a change in clinical practice from using paper 
questionnaires for patients receiving biological treatment and inconsistent 
questioning of symptoms by doctors and nurses to consistent registration of each 
patient’s symptoms on the touch screens upon arrival to the clinic. Today, the touch 
screens are operational and constitute an important part of the clinical management 
of IBD patients at Aalborg University Hospital. 
In the second study, we conducted a real-life study of infliximab use during the first 
16 years post-marketing in the North Denmark Region. We demonstrated a change 
in prescription patterns over time. This study suggested that patients with ulcerative 
colitis today are younger at first prescription of infliximab than in previous years, 
that patients with Crohn's disease now tend to have a shorter time from diagnosis to 
first treatment with a biologic, and that there is a general tendency towards longer 
duration of treatment today as compared to previous years. 
In the third study, we wanted to evaluate the effect of premedication with 
corticosteroids before infliximab treatment on the formation of antibodies towards 
infliximab, on infliximab trough levels, and on the elimination rate of infliximab. 
For a longer period, this question remained unanswered at the Department of 
Gastroenterology at Aalborg University Hospital, where premedication with 
corticosteroids was administered routinely. We were able to use GASTROBIO for 
identification of patients eligible for this study to facilitate recruitment. This study 
was conducted in collaboration with doctors at Aarhus University Hospital, where 
premedication was not administered routinely. We were not able to show any effect 
of premedication and therefore this routine has now been changed in Aalborg. 
Collectively, the three studies contribute to showing that it is feasible and beneficial 
to establish a database with clinical measures and patient reported outcomes for the 
clinical management of patients with inflammatory bowel diseases, for observational 
research, for identification of patients for trials, and for data transfer to a mandatory 




Med muligheden for at behandle de inflammatoriske tarmsygdomme Crohns 
sygdom og colitis ulcerosa med biologiske lægemidler i slutningen af 1990'erne, er 
der sket en revolutionerende forandring i behandlingsmulighederne for disse 
sygdomme. De nye lægemidler er imidlertid dyre, og samtidig med et ønske om at 
kunne følge behandlingseffekt klinisk og i forskningssammenhæng har der været et 
ønske om at have overblik over økonomien både på de enkelte afdelinger, men også 
i større samfundssammenhæng. Deraf kom også kravet i Danmark om en 
kvalitetsdatabase vedrørende brugen af disse lægemidler. 
På Aalborg Universitetshospital havde man ajourført alle regionens patienter med 
inflammatoriske tarmsygdomme fra 1978 til 2002 i en database, der ikke længere 
var funktionel. I 2014 var der ikke meget systematisk registrering i det gamle 
format, og man følte et behov for en ny database, der kunne inddrage patienternes 
symptomer i form af patient rapporterede oplysninger, samtidig med at klinikeren 
kunne få et hurtigt overblik over patientens behandling og effekt. Samtidig var det 
ønsket, at databasen skulle levere data til den nationale kvalitetsdatabase. Ph.d.-
studiet omhandler etableringen af en sådan database og anvendelsen af den. 
Løsningen blev GASTROBIO, der er en web-baseret database, som har tilknyttede 
touch skærme, hvor patienten rapporterer sine symptomer inden hver konsultation 
hos lægen eller sygeplejersken og inden hver infusion af biologisk medicin. 
Patientens indtastninger på touch skærmene, herunder validerede livskvalitet og 
sygdomsaktivitetsscores, samt bivirkningsregistrering, rygevaner, og vægt, er 
umiddelbart tilgængelige for sundhedspersonalet efterfølgende. Således kan 
patientens indrapporteringer diskuteres direkte i forbindelse med konsultationen. 
Desuden giver databasen et overblik over patientens sygdomsvarighed, udbredelse, 
medicin, endoskopier, paraklinik, familiære dispositioner, højde, vægt osv. 
Databasen er således et værktøj til det kliniske arbejde. Den gamle database kunne 
overføres til GASTROBIO, og dermed var den tidligere erhvervede viden bevaret, 
hvilket styrkede forskningsmulighederne. Nogenlunde samtidig med etableringen af 
GASTROBIO blev der nedsat en styregruppe med ansvar for tilblivelsen af en 
kvalitetsdatabase på området. GASTROBIO er fuldt kompatibel med 
kvalitetsdatabasen, og transmitterer data månedligt uden ekstra arbejde og 
dobbeltindtastninger for personalet. 
I forbindelse med etableringen af GASTROBIO opstod følgende tre spørgsmål: 1) 
Er det muligt at overgå til touch skærme i ambulatoriet? 2) Hvordan er det gået i det 
kliniske arbejde med behandlingen med det biologiske lægemiddel infliximab de 
første 16 år efter registrering? 3) Kan vi undersøge et klinisk spørgsmål ved at finde 
patienter i databasen, som kan indgå? 
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I det første studie undersøgte vi validiteten af touch-skærme i ambulatoriet frem for 
papir spørgeskemaer. Vi viste, at det var muligt at bruge touch-skærme, og vi 
erfarede, at datakompletheden blev optimeret. Tidligere brugte man 
papirspørgeskemaer til patienter, der fik biologisk behandling, mens øvrige patienter 
blev spurgt om deres symptomer af lægen med varierende regelmæssighed, men nu 
udfylder alle patienterne spørgsmålene via touch-skærmene. Touch-skærmene er i 
brug og en vigtig del af den daglige behandling af patienter med inflammatoriske 
tarmsygdomme på Aalborg Universitetshospital. 
I det andet studie foretog vi en deskriptiv undersøgelse af de første 16 år, infliximab 
har været på markedet i Danmark og fik bekræftet vores hypotese, at der i løbet af 
årene er sket en ændring i ordinationen af infliximab. Vi kunne vise, at patienter 
med colitis ulcerosa er blevet yngre ved første ordination, patienter med Crohns 
sygdom har kortere tid fra sygdomsdebut til biologisk behandling, og generelt at der 
er en tendens til, at patienterne får behandlingen i længere tid i de senere år 
sammenlignet med tidligere år. 
I det tredje studie ønskede vi at undersøge, om forbehandling med 
binyrebarkhormon forud for infliximab behandling kunne reducere antistof-dannelse 
mod infliximab, kunne øge dalværdier af infliximab og ændre 
eliminationshastigheden. Det var et spørgsmål, der havde optaget Medicinsk 
Gastroenterologisk afdeling, Aalborg Universitetshospital, gennem længere tid. Vi 
kunne bruge GASTROBIO til at identificere de patienter, der var relevante for 
studiet og på den måde rekruttere patienter. Studiet blev lavet sammen med læger på 
Aarhus Universitetshospital, hvor man ikke rutinemæssigt giver forbehandling, og vi 
kunne ikke vise en gunstig effekt af binyrebarkhormon-behandlingen. Det har haft 
den konsekvens, at man nu er stoppet med at give denne forbehandling 
rutinemæssigt i Aalborg. 
Samlet set bidrager de tre studier til at vise, at det er muligt og nyttigt at etablere en 
database mhp. monitorering af behandling af inflammatoriske tarmsygdomme, 
observationel forskning, identifikation af patienter til kliniske forsøg og samtidig 
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CHAPTER 1. INTRODUCTION  
1.1. INFLAMMATORY BOWEL DISEASES 
The inflammatory bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis 
(UC), are autoimmune diseases with an etiology not fully comprehended. It is 
generally believed that the etiology is multifactorial. Thus, genetics, environmental 
and immunogenetic factors, as well as microbiota disequilibrium are most likely 
involved. The two diseases are on the rise worldwide with the highest incidence and 
prevalence in the developed countries
1–7
. In Denmark, where the incidence is among 
the highest in the world, the prevalence is not well established, but the latest 




The first accounts of what was later known as Crohn's disease are believed to date 
back to the 1700s
9
, but not until 1932 came the first actual description of the disease 
when Dr. Bernard Crohn and colleagues at Mount Sinai University described 14 
cases of regional ileitis with similar clinical and pathological findings
10
. This disease 
entity was later named after Dr. Crohn. Ulcerative colitis is less well described 
historically. Descriptions of bloody diarrhea and dysentery are found in antiquity
11
. 
The first case description is credited to Wilks in 1859
12
, but was later found to be 
Crohn's colitis
13
. However, in 1875, Wilks and Moxon made a detailed description 
of a syndrome of simple ulcerative colitis
14
. In 1960, Lockhart-Mummery and 
Morson made the phenotypic distinction between the two disease entities
15
.    
The diseases are chronic, relapsing and affect many aspects of the patient's life. IBD 
is associated with marked morbidity, and even a slightly elevated mortality for 
Crohn's patients
16
. There is no cure, and before the mid 1900s, therapy was primarily 
surgical. From the 1950's to the 1990's, the evolution of treatment for IBD was slow. 
Sulfasalazine was first used in the treatment of ulcerative colitis in 1941
17
. It was a 
stroke of luck that lead to the establishment of the drug's effect, as it was 
administered for patients in rheumatology for arthralgia and turned out to also 
reduce their diarrhea
11
. In 1977, it was discovered that it was 5-aminosalicylate (5-
ASA) that was responsible for the positive effect on UC
18
. In a randomized 
controlled trial from 1955, Truelove and Witt showed that hydrocortisone was 
highly effective in ulcerative colitis
19
. Corticosteroids were also shown to have 
effect in CD
20
, but they were generally unfit for prophylactic use, and unfortunately 
they proved to be associated with a high level of relapse and steroid-dependency
21
. 
In 1980, the for other indications well-known drugs azathioprine (AZA) and 6-
mercaptopurine (6-MP) were shown to be able to sustain remission
22
 in IBD. In 
1995, Feagan and colleagues further showed that methotrexate was effective in 
improving symptoms and reducing the need for prednisolone
23
, and in  maintaining 
remission
24
. However, for patients with intolerable side effects to or lack of effect of 
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these drugs, there was no alternative to surgery. Therefore, a need for new therapies 
was evident, and in the late 1990's, a new era in the treatment of IBD began with the 
introduction of anti tumour necrosis factor alpha (anti-TNF) therapy.   
1.2. BIOLOGICAL THERAPY 
The first available biologic drug for IBD was infliximab (IFX). It was registered in 
the United States in 1998, and in Denmark in 1999. IFX is a chimeric monoclonal 
IgG1 antibody being a combination of 75% human and 25% murine antibody amino 
acid sequences. This antibody targets anti-TNF alpha, which is a pro-inflammatory 
cytokine, by blocking its ability to interact with the TNF receptors, thus inhibiting 
the production of other pro-inflammatory cytokines involved in the systemic 
inflammatory response. IFX also blocks the anti-TNF mediated enhancement of 
leukocyte movement or migration from the blood vessels into the tissues as well as 
the release of adhesion molecules
25–27
. IFX thus causes a reduction of inflammation 
in systemic immune response by specifically blocking the TNF-alpha receptor. IFX 
is termed a biological drug, because it is manufactured from recombinant purified 
DNA, in this case from mouse and human antibodies. 
The administration is intravenous, as the drug would otherwise be destroyed by the 
digestion tract. The dosage is 5-10 mg/kg initially at week 0, 2 and 6, and 
maintenance therapy every 8th week if indicated
27
. 
Studies on efficacy and safety of IFX especially in clinical trials are numerous
26,28,29
. 
Large nationwide population based cohort studies have addressed both the risk of 
infections and cancer
30,31
. However, in order to optimize the conduct of real-life 
studies on the use of biologics in unselected patient cohorts, a clinical database with 
recording of phenotypic features as well as patient reported outcomes (PROs) is 
pivotal. 
1.3. THE ESTABLISHMENT OF THE DATABASE 
At the Department of Gastroenterology and Hepatology at Aalborg University 
Hospital, the IBD team had previously collected subsequent data on IBD patients 
from 1978 and onwards for research purposes in the so-called DARIBO registry. 
These data have been reported in several papers
1,2,32,33
. However, while the data on 
all patients in the Region were updated by 2002, the following years showed a 
declining completeness of the data, and by 2014 only a small percentage of new IBD 
patients were registered. Moreover, patient histories were not updated.  
Along with the new costly biological treatments, the need for a database re-emerged. 
As technology advanced, the objective for a tool to monitor the treatment of the 
individual patient as well as for research purposes had become feasible. The solution 
became a database created by the PhD student in collaboration with Zitelab Aps, 
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hence forming the basis for the present PhD project. The underlying IT solution was 
an open source web-based technology. It was based on Plone (www.plone.org) in 
combination with R (www.r-project.org) and MySQL (www.mysql.org), which 
enables rapid development circles without any licensing costs or other economic 
bindings. It was named GASTROBIO.  
As Aalborg University hospital was (and still is) the only hospital in the North 
Denmark Region (~583,000 inhabitants) to offer biological therapy to IBD patients, 
initially GASTROBIO was supposed to be a registry for patients receiving 
biological therapy. However, a large amount of data was already available in 
DARIBO and it was therefore decided that the new database should comprise all the 
IBD patients from DARIBO (1978-2002) and all IBD patients diagnosed and treated 
thereafter.  
The database was aimed to be a tool for the clinician as well as for the patient, so 
that data collection in the future would be easier and more regular. Thus, the 
database was built up with a variety of relevant information about the patient.  
Along with this, the PhD student introduced touch screens in the outpatient clinic as 
online questionnaires for patients to answer questions about their symptoms and 
general well-being before each consultation or biological treatment. 
 
1-1 Touch screens at the IBD outpatient clinic at Aalborg University Hospital 
The establishment of this database and its use became the basis for this PhD thesis. 
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1.4. CLINICAL MANAGEMENT, RESEARCH AND QUALITY 
ASSURANCE 
The PhD study covers clinical management and research while quality assurance is a 
separate entity.  
The database is fully able to handle quality assurance, but a National Clinical 
Quality registry for biological therapy (BIOIBD) with funding from the Danish 
Regions has been established under the Centre of Competence for Nationwide 
Clinical Registries
34
. The PhD student is a member of the steering committee of this 
registry and has secured the compatibility of GASTROBIO to BIOIBD. Therefore, 
at Aalborg University Hospital, the clinicians spend no extra time entering data into 
BIOIBD, as GASTROBIO can readily transfer the data required. 
It is mandatory to report to the national registry. Figure 1 outlines the differences in 
types of registries. 
 
1-2 Type of Registry 
 
1.5. RESEARCH POSSIBILITIES 
Three different initial research themes emerged in relation to the establishment of 
GASTROBIO. 
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1) Studying the validity of the touch screen questionnaires 
2) Describing the patients receiving biological treatment in the database 
3) Using the database for identification of patients for intervention studies 
1.6. VALIDATION OF TOUCH SCREENS 
A study from 2010 had shown that touch screens in rheumatology generate valid 
data, are well accepted by the patients, and display a number of advantages 
compared to paper versions
35
. This study validated touch screens for patients with 
rheumatoid arthritis, psoriasis arthritis, and ankylosing spondylitis in the Danish 
National Rheumatology Registry, DANBIO. Touch screens have been evaluated in 
several other studies. De Bree and colleagues suggested that touch screens collecting 
health related quality of life and distress data on head and neck cancer patients were 
functional for clinical and scientific documentation
36
. In 2008, Ramachandran and 
colleagues tested a visual analog scale on paper and touch screens in random 
subjects in the Tucson metropolitan area in Arizona, USA
37
. They found the touch 
screen mode to have an acceptable agreement with the paper mode. 
Touch screens in the outpatient clinic at the Department of Gastroenterology and 
Hepatology at Aalborg University Hospital where patients tap the answers to their 
symptomatology, general wellbeing, weight, and smoking habits at every visit have 
been operational since January 15, 2015. 
Previously in Aalborg, the physician asked the patients these questions, but not 
consistently. When the patients came for biological therapy, they filled out a 
questionnaire in paper. 
1.7. DESCRIPTIVE STUDY OF THE USE OF INFLIXIMAB 
Several studies on efficacy and side-effects in regards to biological agents have been 
published
26,28,45–51,29,38–44
. It has thus been shown that IFX is both effective and safe. 
However, large population based studies on the number of patients being treated 
with the individual drugs, the patient category, and the number of patients who 
terminate therapy for different reasons are rare. It has been addressed in one study 
by Caspersen and colleagues from 2008, concluding that IFX is safe and generally 
well tolerated, although rare but severe adverse events occurred
49
. This study dates 
back to the beginning of the biological era from 1999-2005, when the use of these 
medications was limited to a small subset of patients. Other studies have shown a 
tendency towards patients being treated with biological drugs at a younger age in 
recent years
52,53
, but as the experience with prescribing these drugs increase, this 
may change over time. Desai and colleagues also suggested that patients older than 
age 60 were more likely to terminate the biological therapy earlier than younger 





. Pressman and colleagues could already in 2008 show that the use of 
infliximab had increased substantially during the first 10 years post-marketing
53
.  
Since the introduction of IFX at Aalborg University Hospital in 1999, it has been 
evident that the use of the drug has increased every year. Therefore, there was a 
presumption that a changing prescription pattern had emerged. With the unique data 
collection on all patients receiving IFX in a geographically well defined population, 
it was now feasible to undertake a large population based descriptive study of the 
first 16 years of administration of IFX in the North Denmark Region with the 
detailed knowledge of treatment duration and causes for discontinuation. 
1.8. IDENTIFICATION OF PATIENTS FOR AN INTERVENTION 
STUDY 
With the introduction of IFX, consisting of 25% murine protein, came an awareness 
of allergic reactions. Antibodies towards IFX were acknowledged and believed to be 
responsible for both loss of clinical effect
54
, but also possibly infusion reactions
55
. It 
is well known that infusion reactions do not occur during the first infusion, but 
increases in incidence during the subsequent infusions. In the ACCENT I 
randomized trial on maintenance therapy with IFX for CD in Lancet in 2001, 
Hanauer and colleages showed that the lowest incidence of infusion reactions 




A long standing unanswered question for the physicians at Aalborg University 
Hospital, was the effect of premedication in IFX therapy. In Denmark, there have 
been different approaches to premedication with corticosteroids before infliximab 
infusions. Some centers have done it consistently, some centers have never done it, 
and some centers have done it when the patient is not naïve to infliximab.  
The theory that the risk of allergic reactions is reduced by premedication with 
corticosteroids has been the reason for this practice at the Department of 
Gastroenterology and Hepatology at Aalborg University Hospital. All patients 
receiving IFX in Aalborg have received premedication with corticosteroids from 
1999 to 2017. However, at Aarhus University Hospital this was not the case, and 
therefore, with the newly established database, it was now possible to conduct a 
study between the two centers. 
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CHAPTER 2. OBJECTIVES 
2.1. OBJECTIVE PAPER I 
The overall objective of this study was to examine the feasibility of introducing 
patient involvement through touch screens at the outpatient clinic. 
2.2. OBJECTIVE PAPER II 
With this study, we aimed: 
1. To present an overview of real-life use of IFX in a population-based cohort, 
the North Denmark Region, from 1999-2014, comprising 
a.  Characteristics for the patients: gender, age, weight, height, 
smoking habits, disease duration, disease extension, family history 
of IBD 
b. Indications for biological therapy in the cohort 
c. Causes for termination of biological therapy, i.e., allergic 
reactions, side effects, surgery, death 
in order to describe changes in prescription patterns. 
2.3. OBJECTIVE PAPER III 
The third study had the objective to use the database to easily identify patients for 
research. 
The objective of this study was to evaluate pretreatment with corticosteroids before 
infusion with infliximab in patients with Crohn’s disease in order to determine the 
effect on IFX trough levels, the time of IFX elimination, and anti-TNF alpha 
antibody level in the blood. 
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CHAPTER 3. MATERIALS AND 
METHODS 
3.1. GASTROBIO 
The database contains variables regarding type of disease (UC, CD, IBD-
unclassified, or other), family history, treatment (biologics, standard treatment), 
laboratory results (C-reactive protein, hemoglobin, albumin, fecal calprotectin), side 
effects, smoking, age, height, surgery, pregnancies, endoscopies, extent of disease, 
and activity scores. The Short Health Scale (SHS)
56,57
 and Short Clinical Colitis 
Activity Index (SCCAI)
58
 were used for patients with UC and SHS and Harvey 
Bradshaw Index (HBI)
59
 for patients with CD. 
 














Bowel frequency (night)  
0 0 
1-3 1 










Blod in stool  
None 0 
Trace 1 
Occasionally frank  2 
Usually frank  3 
  
General well-being  
Very well 0 
Slightly below par 1 
Poor 2 
Very poor 3 
Terrible 4 
  
Extracolonic manifestations 1 per manifestation 
Arthritis  
Uveitis  
Erythema nodosum  
Pyoderma gangrenosum  
Table 3 The Short Clinical Colitis Activity Index 
Symptom Score 
  
General well-being (yesterday)  
Very well 0 
Slightly below par 1 
Poor 2 
Very poor 3 
Terrible 4 
  






Number of liquid stools per day (yesterday)  
If no stomi 1 per liquid stool 
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Definite and tender 3 
  
Extraintestinal manifestations 1 per manifestation 
Arthralgia  
Uveitis  
Erythema nodosum  
Aphthous ulcers  
Pyoderma gangrenosum  
Anal fissure  
New fistula  
Abscess  
Table 4 The Harvey Bradshaw Index 
The data are collected real-time, as patients stop by the touch screens at every visit, 
both for a consultation with at doctor or a nurse, but also before biological treatment. 
The result from the touch screen is immediately available in the database which the 
doctors and nurses access using a web-browser. 
 
3-2 Patient board in GASTROBIO. Colors are defined by the total activity score as an 
indication of severity of disease activity 
For research purposes, a search of the database can be made for relevant variables 
and dates. 
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3.1.1. ETHICAL CONSIDERATIONS 
The GASTROBIO registry has been approved by the Danish Data Protection 
Agency as a Research registry (2008-58-0028) and by the North Denmark Region as 
a clinical treatment database. The Danish Health Authority has approved the 
collection of data from patients from the whole North Denmark Region as a 
continuation of the old (DARIBO) database (3-3013-720/1). 
Regarding Paper I, all patients consented to participate. However, according to 
Danish law, the study did not require further approval from the Ethics Committee. 
Regarding Paper III, the Regional Committee on Health Research Ethics approved 
the study (N-20140003). 
3.1.2. STATISTICAL APPLICATION 
Analyses were carried out using Stata (Stata/IC 12.1 for Windows, www.stata.com). 
We applied 2-sided tests with corresponding P values, using a significance level of 
5%. For further details, please see paragraphs of statistics under the description of 
each of the three papers. 
3.2. PAPER I 
3.2.1. PATIENTS 
Over a 30-day period (from 21 August 2015 to 18 September 2015), 57 UC patients 
and 75 CD patients were invited to participate in this validation study. The patients 
came to the outpatient clinic for a consultation with a physician or for biological 
treatment. 
They were all asked to fill out the paper questionnaires as well as the touch screen 
questionnaires. A random group of the patients filled out the paper questionnaires 
first and the rest used the touch screens first. 




3-3 Patients in the study 
3.2.2. QUESTIONNAIRES 
Both UC and CD patients received identical questions on weight, smoking habits, 
and adverse events. UC patients further filled out the SHS scale and SCCAI score 
while CD patients filled out the SHS scale and HBI score. 
The SHS is a visual analog scale and on the touch screens patients were asked to 
place a mark on the scale. Subsequently the system calculates the score from 0 to 
100. However, on the paper questionnaires, patients were asked to give a number 
between 0 and 100. The questions adding up to the SCCAI and HBI scores were 
answered by checking off a box with the relevant answer for every question. 
3.2.3. STATISTICAL ANALYSES 
The Spearman correlation coefficient was calculated for the SHS scores, and Bland-
Altman plots were used for visualization. 
The Kappa-statistic measure of agreement was performed on the SCCAI and HBI 
scores. This was done both raw and weighted according to disagreements. 
McNemar's exact significance test was used to test for differences in missing data 
patterns. 
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3.3. PAPER II 
3.3.1. STUDY POPULATION 
All IBD patients treated with infliximab in the North Denmark Region between 
1999 and 2014 were included in the study. 
Infliximab for CD patients had been administered since 1999 and for UC since 2005 
at Aalborg University Hospital. 
 
3-4 Study population 
3.3.2. DEFINITIONS 
Indications were divided into "Acute severe UC", "Chronically active UC", 
"Luminal CD", and "Fistulizing CD". 
Disease extent was divided into "Leftsided" and "Pancolitis" for UC patients, and 
"Upper gastroentestinal disease", "Ileal", "Ileocolonic", and "Colonic disease" for 
CD patients according to the Montreal classification
60
. 
The time of exposure was divided into two time periods: 2005-2009 and 2010-2014 
for UC patients, and 1999-2009 and 2010-2014 for CD patients. 
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3.3.3. STATISTICAL ANALYSES 
Linear regression was performed to assess changes over time. Thus age at exposure 
and disease duration were analyzed by year of first IFX exposure. In addition, a 
sensitivity analysis was performed, removing the years 1999-2003. 
Changes over time in "Disease extent" and "Indications" were examined between the 
two time periods using the 
2
 test. 
Kaplan-Meier curves were used to evaluate differences in time to discontinuation 
between the two time periods. 
3.4. PAPER III 
3.4.1. STUDY POPULATION 
Two groups of CD patients with or without concomitant pre-medication with 
corticosteroids in maintenance therapy with infliximab for 12 months (12-18 
months) from two Danish centers (Aalborg University Hospital and Aarhus 
University Hospital) participated in this study between 2015 and 2017. All patients 
were naïve to biologics. In Aalborg, patients eligible for the study were identified in 
GASTROBIO which made inclusion into the study more effortless. 
Premedication (if given) consisted of 40 mg prednisolone administered orally at 
home on the day before the infusion and 40 mg of methylprednisolone 
(SoluMedrol®) intravenously right before the infusion. 
3.4.2. BLOOD SAMPLES 
Blood samples were taken before, one hour after and one week after the IFX 
infusion and IFX concentration analyses were performed. Anti-TNF alpha antibody 
concentration was analyzed for the blood sample taken before the IFX infusion. 
3.4.3. STATISTICAL ANALYSES 
Linear regression was performed to test for differences in the IFX and IFX antibody 
concentrations with or without premedication with corticosteroids. Furthermore, 
tests for interaction were made regarding concomitant azathioprine (AZA) use. 
Logarithmic transformation was made in order to obtain normally distributed data 
regarding IFX concentrations and IFX antibody concentrations, but it was not done 
for the half-life of IFX as these data were normally distributed. For the data 
submitted to logarithmic transformation, geometric means and coefficients of 
CHAPTER 3. MATERIALS AND METHODS 
33 
variation were reported, and for the IFX half-life data, means and standard 
deviations were reported. 
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CHAPTER 4. RESULTS 
4.1. PAPER I 
The study included 54 UC patients (52% males), and 74 CD patients (47% males). 
Sixty-one percent of the UC patients and 70 percent of the CD patients filled out the 
touch screens first.  
Completeness of SHS scores was seen in 46 UC patients (85%) and 59 CD patients 
(80%). 
SCCAI scores were complete for 51 UC patients (94%). HBI scores were completed 
by 62 CD patients (84%). 
There were 5 UC patients (9%) and 2 CD patients (3%) above 65 years of age. No 
separate analyses were made on these patients, but a number of misunderstandings 
of the questionnaires were reported in connection to these patients. 
4.1.1. CORRELATION 
SHS scores demonstrated a high correlation (Spearman) of 0.92 for both CD and UC 
regarding SHS on touch screens and SHS on paper. Bland-Altman plots showed no 
difference between the two modalities. 
There was a high agreement (Kappa-statistic measure of agreement) for both SCCAI 
scores (78% raw, and 98% weighted) and HBI scores (65% raw, and 97% 
weighted). This indicated that patients gave the same response on the touch screen 
and on paper. 
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4-1 Bland-Altman plots of SHS for UC and CD. The full-drawn line marks the zero value on 
the ordinate. The dotted horizontal lines mark the mean difference and the limits of 
agreement61. 
4.2. PAPER II 
This study found 717 IBD patients receiving biological therapy in the study period 
(1999-2014). Of these, 623 patients (210 with UC and 413 with CD) had initiated 
treatment with IFX as their first biologic. Of the UC patients, 51% were males 
whereas only 41% of the CD patients were males. 
4.2.1. AGE AT EXPOSURE 
For UC patients, the mean age at first exposure to IFX decreased by 10 months per 
calendar year during the study period from 2005-2014 (95% CI, -1.58 to -0.03; 
P<0.05). This was not the case for CD patients, nor after removing years 1999-2004 
as a sensitivity analysis. 
4.2.2. DISEASE DURATION 
For CD patients, the mean time from IBD diagnosis to first IFX exposure decreased 
by 7 months per calendar year (95% CI, -0.84% to -0.33%; P<0.001), and after 
removing the first years, thus studying years 2004-2014 only, this time was still 
decreased by 5 months per calender year (95% CI, -0.72% to -0.01%; P<0.03). No 
change in disease duration before IFX exposure was detected among UC patients. 
4.2.3. DURATION OF TREATMENT 
For UC patients exposed to IFX during 2010-2014, the time from initiation of 
treatment to discontinuation of treatment increased compared to years 2005-2009. 
The median interval was 1.11 years compared to 0.34 years (HR 1.42; 95% CI, 1.02 
to 1.98; P = 0.04). 




4-2 Time from infliximab prescription to discontinuation in a population-based cohort of 
patients with ulcerative colitis (n = 208)62. 
4.3. PAPER III 
A total of 57 patients were included in the study. Of these, 31 received 
premedication with corticosteroids. In this group, 11 patients (35.5%) were on 
concomitant immunomodulator therapy with azathioprine, whereas 22 (84.6%) of 
the 26 patients in the other group received azathioprine. Two patients dropped out of 
the study before the one week after blood sample. 
4.3.1. EFFECTS OF PREMEDICATION WITH CORTICOSTEROIDS 
This study showed no effect on premedication with corticosteroids on IFX trough 
levels (geometric mean 7.3 g/mL vs 5.1 g/mL with and without corticosteroids, 
p=0.10), IFX elimination time (10.5 days in both groups, p=0.31), or IFX antibody 
formation (10.0 AU/ml and 6.7 AU/ml p=0.28). However, independently of 
corticosteroid premedication, concomitant use of azathioprine was associated with 
higher IFX trough levels (p=0.023), longer half-life of IFX (p=0.04), and lower IFX 
antibody concentrations (p=0.004). 
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CHAPTER 5. DISCUSSION OF 
RESULTS 
5.1. PAPER I 
5.1.1. FEASIBILITY 
In this validation study, we show that it is feasible to introduce touch screens in the 
IBD clinic. 
Among the strengths of this study is patients’ familiarity with the questions. The 
patients already knew the questions of the HBI and SCCAI scores from the paper 
questionnaires. We therefore consider confounding due to misunderstanding of 
questions less likely. Also, on paper it is easier to omit an answer. On the touch 
screen, patients have to acknowledge that they are omitting an answer before being 
able to proceed. Furthermore, on the touch screens patients have no risk of receiving 
the wrong questionnaires, whereas when paper questionnaires are handed out by the 
staff, UC patients could be given CD questionnaires and vice versa. This was seen in 
the study. 
However, some limitations of the study should be addressed. First, the study was 
undertaken during only one day for the individual patient. Patients were asked to fill 
out both paper as well as touch screen questionnaires consecutively. Therefore, the 
results could be positively biased if patients remembered what they just answered. In 
a study of patients with rheumatological disorders by Schefte and Hetland
35
, the 
same approach was used, whereas in the validation of the SHS in UC by Hjortswang 
and colleagues
57
 and in CD by Stjernman and colleagues
56
, the retesting was done 
after two and four weeks, respectively. This, however, is hardly a feasible approach 
to IBD patients whose symptoms are likely to change during the course of even a 
short time. Second, in the HBI score there is a subscore "Abdominal mass". This is 
supposed to be filled out by the physician, but we let the patient evaluate this 
subscore. Also, patients with previous surgery were asked to fill out the 
questionnaires, but HBI is not validated for this group of patients. Third, the visual 
analog scale had not been used previously on paper in our clinic. Patients were 
asked to name a number from zero to 100 on the paper questionnaires whereas on 
the touch screens they were presented with the actual line of the visual analog scale. 
Furthermore, whereas our study found a comparable correlation between paper and 
touch screen versions of this score to the validation studies
56,57
, correlation is not the 
appropriate measure of agreement between measurement methods according to 
Bland and Altman
63
. Therefore, this renders some uncertainty regarding our results 
on the SHS score and further studies are needed. 
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In conclusion, with this study we found it feasible to introduce touch screens with 
PROs in the IBD outpatient clinic. 
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5.2. PAPER II 
5.2.1. PRESCRIPTION PATTERNS 
This population-based cohort study suggests a change in prescriptions patterns 
towards introducing biologics at a younger age in UC, after a shorter disease 
duration in CD, and in patients with less extensive disease as well as continuing 
biologics for a longer time in recent years.  
The study has obvious strengths. It covers a long period of time, namely 16 years of 
real life use of IFX post-marketing. It is based on a large unselected population 
which is geographically well defined to the Northern part of Jutland and comprises 
around 583,000 citizens. There is only one center involved in collecting the data 
with the same core of physicians. 
There are potential limitations to be mentioned. First, while Aalborg University 
Hospital is the only center in the region to offer biological treatment, there are other 
centers who refer patients to Aalborg for biological treatment. Thus, for some 
patients who are not cared for in Aalborg primarily, there can be a referral delay. 
However, this practice remains unchanged throughout the study period. Second, the 
distribution of missing data is unknown. Manual scrutiny of patient charts in order to 
retrieve information on disease extent at time of diagnosis was performed, but a 
substantial amount of missing data remains. Third, it is known that there has been a 
change in examination practice towards increased usage of magnetic resonance 
enterography (MRE). The study has not accounted for this. Fourth, there are no data 
on hospitalization. 
The findings of this study are in agreement with those of other studies. Pressman 
and colleagues found that younger patients were more likely to initiate treatment 
with IFX
53
. This study was a cohort study of CD patients within a defined 
population. The comparison was between patients initiating IFX therapy and 
patients who did not. Our study included patients who initiated IFX therapy and the 
comparison was between time periods. Desai and colleagues showed that patients 
older than 60 years of age had a shorter time to discontinuation
52
. This study was a 
retrospective case control study of IBD patients conducted at a single referral center. 
Our findings that UC patients were younger at initiation of therapy, could therefore 
explain the longer time to discontinuation seen in regards to that study.  
In conclusion, we found a change in IFX prescription patterns towards a younger 
age at prescription, a shorter disease duration, and a longer duration of treatment 
throughout the first 16 years of IFX administration in the North Denmark Region. 
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5.3. PAPER III 
5.3.1. PREMEDICATION WITH CORTICOSTEROIDS 
This cross-sectional observational study of infliximab treated Crohn's patients with 
or without premedication with corticosteroids was not able to find any effect of this 
premedication on the formation of IFX antibodies, IFX trough levels, or elimination 
rate of IFX regardless of concomitant AZA. 
Previous studies in rheumatology have addressed this question with diverging 
conclusions. Focus has been on infusion reactions primarily where Choquette and 
colleagues found no effect of premedication
64
 and Bartoli and colleagues found a 
relative risk of infusion reactions 2.5 times higher in a no premedication group 
compared to a group of patients receiving a combination of paracetamol, 
esomeprazole, hydrocortisone, and chlorpheniramine maleate (an antihistamine)
65
. 
In Gastroenterology in 2003, Farrell and colleagues performed a 16-week double-
blind, placebo-controlled study of 80 consecutive patients with refractory Crohn's 
disease
66
. One group received 200 mg of hydrocortisone bolus and the other 
placebo. It was found that hydrocortisone significantly reduced antibody formation, 
and they suggested that premedication should be considered in some patients. 
However, in IBD in 2017, Gold and colleagues reported no effect of corticosteroid 
premedication on infusion reactions in a retrospective cohort study comprising 578 
IBD patients and concluded that routine premedication use could not be 
recommended without future randomized control trials
67
. 
In our study, concomitant immunomodulator therapy with AZA was shown to 




The strengths of our study are the standardization of the blood sampling and the fact 
that, to our knowledge, it is the only study evaluating premedication in IFX therapy 
after 12-18 months of therapy in CD patients. 
Potential limitations of this study are the small sample size making it possible that 
there was in fact an effect of premedication which was overlooked. However, we did 
not register even a slight tendency towards effect. Also, in this study patients were 
on a stable dose of IFX during at least 12 months. Thus any intolerable infusion 
reactions or side effects would have caused the patients to terminate the therapy 
earlier, making these patients not eligible to participate which might cause selection 
bias. 
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In conclusion, we were not able to detect a difference in IFX antibody formation, 
IFX trough levels, or IFX elimination rate in patients receiving corticosteroid 
premedication, leading to a change in practice in our clinic. 
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CHAPTER 6. CONCLUSION AND 
CLINICAL IMPLICATIONS 
The establishment of a database that serves as a tool in the clinical management of 
patients with IBD, has proved to enhance the management of patients due to easy, 
quick access to all  relevant information on the individual patient with regards to 
their IBD diagnosis, symptoms, treatment, side effects, and procedures. This is 
currently not possible in the electronic patient file systems available in Denmark. 
The fact that PROs are central in the structure of this database, is beneficial to the 
individual patient and very helpful for the physician in the clinical management of 
the patients' therapy. The readily accessible data on for example number of patients 
undergoing specific treatments makes it potentially time- and money saving for the 
departments as well as society. 
With the studies of the present thesis, we have specifically shown that the 
introduction of touch screens in the outpatient clinic is feasible and it is, as 
mentioned, now operational in the outpatient IBD clinic at Aalborg University 
Hospital. Before the touch screens, only patients receiving biological treatment were 
given a paper questionnaire. For all other IBD patients, the physician would enquire 
about their symptoms, and the consistency of recording of symptoms this way was 
varying. Therefore, we find that data completeness has increased. 
We have further provided knowledge that informs and guides our treatment with 
biologicals. Changes towards younger age at prescription of biologic drugs and a 
longer treatment period are challenging a health care system, where resources are 
scarce. Every year there is an increasing number of patients being treated with 
biologics at the IBD outpatient clinic in Aalborg (Figure 6-1). This has recently been 
illustrated as part of budget negotiations.  
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6-1 Number of biological infusions in Aalborg by year 
 
Lastly, our studies have changed clinical practice, when it comes to premedication 
with corticosteroids. The lack of effect on corticosteroid premedication in IFX 
treatment of patients with Crohn's disease has led to termination of premedication at 
the IBD outpatient clinic at Aalborg University Hospital.  
All in all, this thesis illustrates that it is feasible to establish a database for IBD 
patients serving a number of purposes. This database now guides clinical practice, 
routinely delivers data to the mandatory national quality registry, it serves as a 
source for research, for recruitment of patients for research, and as a research cohort 
for observational studies.  
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CHAPTER 7. FUTURE PERSPECTIVES 
The database and related touch screens have enhanced our treatment of patients. In 
particular, the extended use of PROs may qualify treatment in the future. Further 
development of algorithms for managing patients from home is already ongoing. 
Regular transmission of activity scores to GASTROBIO via an online platform may 
ideally render annual consultations superfluous in the future and enable "on-
demand" consultations. This is both a meaningful use of resources and also more 
patient friendly, as patients no longer have to take time off work to consult with their 
IBD physician at random times. Patients are now able to log on from their home 
personal computer with a link supplied by the clinic. This feature has been tested, 
but is currently not in use. Also development of an app for mobile phones is 
ongoing. 
The establishment of GASTROBIO has provided the IBD team at Aalborg 
University Hospital with a unique ability to perform research. At any given time 
point, there is a complete knowledge of the number of patients in the North 
Denmark Region receiving biological treatment enabling us to perform multiple 
studies both in our own clinic, but also in collaboration with other clinics and 
universities. 
Other gastroenterology databases exist in Denmark, but none contain information in 
this detail on patient level and cover such a large geographical area, and hence the 
data are unique. However, the data in this database can be migrated to other 
databases, if consensus is reached in Denmark or even in Europe, on using the same 
platform everywhere. Furthermore, it is also possible to combine detailed 
information on the approximately 6,600 IBD patients diagnosed during 1978-2016 
with information from the Danish National Hospital Registry (LPR), thereby 
enabling the study of a wide range of long-term outcomes among IBD patients as 
compared to the general population. When such studies are normally conducted by 
use only of the national registries, individual level information on smoking habits 
and phenotypic characteristics are lacking.  
Hence, with the great advantage of detailed patient characteristics in the present 
cohort, we plan to conduct a number of future studies on  
 the development of primary sclerosing cholangitis and cancer in IBD 
patients. Are there phenotypic similarities in these patients? 
 the mortality/morbidity in IBD patients in relation to medical therapy, age, 
disease activity, compared to the healthy population 
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 the prognosis of IBD patients receiving biological therapy compared with 
IBD patients receiving standard therapy in regards to symptoms, fistulas, 
surgery, mortality 
In collaboration with others, we are planning the following studies: 
 The Danish IBD biobank (DIB): Predictors of treatment response and 
disease course in patients with inflammatory bowel disease treated with 
biological therapy. Collaboration with Hvidovre, Herlev, Aarhus. 
 ISCAN: Inflammatory Bowel Disease - Scandinavian cancer in IBD study. 
Collaboration with Oslo, Norway, and Sweden. 
 Extra Intestinal Manifestations in IBD. Collaboration with Department of 
Infectious Diseases, Aalborg University Hospital and Division of 
Gastroenterology, Department of Medicine, University of California, San 
Francisco. 
 Stem cells for fistulas - Aarhus University Hospital in collaboration with 
multiple Danish centers. 
Overall, the possibilities are numerous when data are being collected prospectively 
and real-time as is the case with GASTROBIO. 
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Paper I: Touch screens as a tool in 
patient care in the IBD outpatient clinic  
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ABSTRACT
Objective: We have introduced online touch screens in the waiting room for patients with ulcerative
colitis (UC) or Crohn’s disease (CD) for recording of symptoms before their consultation. This has made
disease activity scores readily available to the physician in our newly established database, ‘Gastrobio’.
We wanted to validate the use of touch screens compared to paper questionnaires.
Material and methods: A total of 54 patients with UC and 74 patients with CD were included in the
study. The UC patients filled out the Short Health Scale (SHS) and Simple Clinical Colitis Activity Index
(SSCAI). The CD patients filled out the SHS and Harvey–Bradshaw Index (HBI). Paper questionnaires and
touch screen versions were used in random order and comparison between the two modalities was
made by Spearman correlation test, Bland–Altman plots, and Kappa-statistics.
Results: Among the 128 patients, the two SHS scores (SHS touch versus SHS paper) were found to be
highly correlated (Spearman correlation; 0.92 for UC and 0.92 for CD). Also, on average, Bland–Altman
plots demonstrated a difference close to zero between the two modalities. Agreement between paper
version and touch screen version of SCCAI and HBI scores was also high (Kappa-statistics; 78% raw and
98% weighted for SCCAI; 65% raw and 97% weighted for HBI).
Conclusions: It is feasible to introduce touch screens in the outpatient clinic and to have patients
record their symptoms before the consultation. However, the study may not be representative for eld-
erly patients.
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The two inflammatory bowel diseases (IBD), ulcerative colitis
(UC) and Crohn’s disease (CD), are primarily managed in out-
patient clinics. Symptoms of the diseases are reported by the
patients and form a substantial part of the assessment of dis-
ease activity and the effect of treatment. At the Department
of Gastroenterology and Hepatology at Aalborg University
Hospital, we have introduced online questionnaires on touch
screens in the waiting room instead of paper versions or oral
interview by the physician. This approach has previously been
shown to be feasible in other diseases with different ques-
tionnaires.[1–7] The introduction of the touch screens in our
clinic is part of the establishment of a database, ‘Gastrobio’,
which comprises clinical information on more than 5000 IBD
patients from the North Denmark Region. It is a web-based
solution based on open-source software.
A previous study has validated the use of touch screens in
the Danish nationwide rheumatology registry, DANBIO, show-
ing that the introduction of touch screens is feasible.[1]
DANBIO includes patients with rheumatoid arthritis (RA), psor-
iasis arthritis (PsA), and ankylosing spondylitis (AS) and was
initiated in the year 2000. Since 2005, an online web-based
version of the database based on the use of touch screens
has been available.[8] Every rheumatology outpatient clinic in
Denmark uses this system, but the scores are of course differ-
ent from IBD scores. The use of touch screens in evaluation
of IBD patients has not been validated in Denmark.
Relevant scores in IBD patients are the Short Health Scale
(SHS), the Simple Clinical Colitis Activity Index (SCCAI), and
the Harvey–Bradshaw Index (HBI). The SHS is a score to evalu-
ate health related quality of life. SCCAI and HBI are simple
and obtainable disease specific scores without laboratory
results and diary information.[9,10] Using these scores, we
found it feasible to introduce touch screens for our patients.
We assumed that patients would be less likely to omit
answers on touch screens than on a paper version of the
questionnaires, but we also had the concerns that the elderly
might have trouble with the touch screens.
We hypothesized that there would be no difference
between answers to paper questionnaires and answers to
touch screen questions. Our aim was to compare the two
modalities and to evaluate differences in 1) SHS and SCCAI
scores among UC patients, 2) SHS and HBI scores among CD




Between 21 August 2015 and 18 September 2015, we asked
57 UC patients and 75 CD patients to participate in the pre-
sent study. Patients came to the outpatient clinic at the
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for a scheduled consultation with a physician or for the
administration of a biological agent. Three UC patients and
one CD patient were excluded due to error in procedure (by
mistake, UC patients were given the CD questionnaire and
the CD patient was given the UC questionnaire).
A total of 54 UC patients and 74 CD patients were included
in the study. We planned to ask half of the patients to fill out
the paper questionnaire first. However, some patients reached
the touch screen before we could approach them, why the
number of patients using the touch screen first was 85,
whereas 43 answered the paper questionnaire first.
Immediately after, patients were asked to answer the question-
naire again using the different tool, and, thereby, all patients
completed both paper and touch screen questionnaires.
Questionnaires
All patients received questions on weight, smoking habits,
and adverse events. In addition, the UC patients filled in the
SHS and SCCAI questions and the CD patients filled in the
SHS and HBI questions.
The SHS is a visual analog scale, but the paper version in
our clinic demands a score between zero and 100. The SCCAI
and HBI items are answered by checking off boxes either on
paper or on the touch screen.
The paper questionnaires were self-administered as were
the touch screens. The patients only received help from the
staff upon request. The paper questionnaires were handed
out to the patients upon arrival to the clinic either from the
nurse, doctor, or secretary, and they were asked to approach
the touch screen to enter their symptoms.
The data collected on paper was manually processed and
entered into the statistical program Stata/IC 12.1 for Windows
(StataCorp. 2011. Stata Statistical Software: Release 12. College
Station, TX: StataCorp LP) The data collected on the touch
screens were immediately processed and available in the
Gastrobio database. These data were transferred into Stata for
statistical analysis.
Patients who had omitted a specific answer either on
paper or on touch screen were excluded only for that particu-
lar score when performing subsequent comparison of
answers. Some patients were excluded for a particular sub-
score as it was clear from the charts that they had misunder-
stood the question on paper.
Statistical analysis
The average of the four SHS subscores was calculated for
both the paper and the touch versions and the difference
(paper version minus touch version) was calculated. The same
was done for the SHS subscores. The SCCAI and HBI scores
were compared subscore by subscore.
In order to be able to compare our results with previous
studies on SHS scores, the Spearman correlation coefficient
was calculated for these scores.[11,12] Further visualization
was done by Bland–Altman plots.
For the SCCAI and HBI scores, the Kappa-statistic measure
of agreement was performed on both raw (no acknowledge-
ment of the importance of disagreements) and weighted
(defined weights of importance of disagreements, a disagree-
ment of one point was weighted lower than a disagreement
of three points).
To test for differences in missing data patterns, McNemar’s
exact significance test was performed.
Ethical statement
All patients agreed to participate. According to Danish law,
the study did not require approval from the Regional Ethics
committee.
Results
The 54 included UC patients had a mean age of 43 years
(range 19–74 years) and 52% were males. The 74 included CD
patients had a mean age of 39 years (range 14–78 years)
with 47% being males. All 128 patients filled out both the
paper and touch screen questionnaire in random order and
Table 1 summarizes the characteristics for the two groups.
The Short Health Scale
A total of 46 UC patients (85%) and 59 CD patients (80%) had
complete SHS scores. The two scores (SHS touch versus SHS
paper) were highly correlated (Spearman correlation; 0.92 for
UC and 0.92 for CD). On average, Bland–Altman plots (Figure 1)
demonstrated no difference (mean difference 1.23 for UC and
0.85 for CD).
Some patients (three UC and five CD) had clearly mistaken
the SHS scale on paper especially regarding the general well-
being where they mistook good for bad and vice versa. They
would typically score zero on the touch screen for all four
subscores and 100 on paper for one subscore and zero for
the other three.
The SCCAI and HBI
The SCCAI and HBI scores were evaluated by means of the
Kappa-statistic measure of agreement, which was high (SCCAI:
78% raw, 98% weighted; HBI: 65% raw, 97% weighted) sug-
gesting that patients would give the same score on paper
and touch screen.
Missing data
Missing data was more prevailing in paper versions than touch
versions (Table 2), however, none of the differences proved to
Table 1. Characteristics of patients with inflammatory bowel disease participat-
ing in the validation of touch screens vs. paper questionnaires.
UC CD
N 54 (100%) 74 (100%)
Gender males 28 (52%) 35 (47%)
Gender females 26 (48%) 39 (53%)
Age, mean (min/max) 43 (19/74) 39 (18/78)
Age >65 5 (9%) 2 (3%)
Smokers 9 (17%) 13 (18%)
Non-smokers 45 (83%) 61 (82%)
Stomi Yes 8 (10%)
Stomi No 66 (90%)
Sequence
Touch screen first 33 (61%) 52 (70%)
UC: ulcerative colitis; CD: Crohn’s disease.



























be statistically significant. Only five (9%) UC patients and two
(3%) CD patients were over 65 years of age, and therefore
analyses of distribution of missing answers among the elderly
could not be performed. Of the five UC patients, one 74-year
old patient had misunderstood the SHS well-being score and
had to be excluded for this subscore, and another patient (65
years old) had omitted subscores for the SCCAI and had to be
excluded for this score. The two CD patients (67 and 78 years
of age) had both omitted answers in two SHS subscores and
were excluded from evaluation of these scores.
Discussion
In this validation study of self-reporting of symptoms and
well-being among 128 IBD patients, we observed that touch
screens in the waiting room provided a valid method for data
collection as compared with paper questionnaires.
In our clinic, we have now had more than 1000 patient vis-
its since the touch screens were introduced, and we have not
experienced any major problems in using them. Our touch
screens provide immediate accessibility to the answers for
the physician and this ensures complete recording of patient
related data at every visit since data collection is no longer
dependent on the doctor or nurse remembering to ask all
the questions. Furthermore, the delay related to processing of
paper questionnaires is avoided. The present study confirms
the validity of the touch screen approach as compared to for-
mer questionnaire methods. In rheumatology, similar experi-
ences have been made.[1]
The theory that familiarity makes a difference was sup-
ported by the satisfactorily concordant HBI and SCCAI scores,
which are more familiar to the IBD patients in our clinic than
the SHS scores. This analysis has not been done previously in
other studies.
Table 2. Distribution of complete answers and scores.
UC CD










All 54 54 74 74
SHS total 53 29.3 (23.7) 46 30.1 (26.0) 71 35.0 (23.6) 65 34.4 (24.5)
SHS symptoms 54 28.6 (25.9) 51 28.1 (27.5) 72 32.9 (25.9) 72 32.5 (27.1)
SHS activity 53 25.5 (28.3) 53 25.5 (30.6) 71 32.6 (27.6) 69 31.1 (28.5)
SHS worry 54 34.8 (26.1) 51 36.0 (29.2) 74 38.0 (27.2) 71 38.2 (28.4)
SHS well-being 54 28.1 (23.5) 51 30.5 (31.4) 72 35.2 (25.2) 68 37.8 (29.9)
SCCAI (total) 54 2.9 (3.0) 51 2.7 (2.9)
Bowel frequency day 54 0.2 (0.7) 53 0.3 (0.7)
Bowel frequency night 54 0.2 (0.4) 53 0.2 (0.4)
Urgency of defecation 54 0.7 (0.8) 54 0.6 (0.7)
Blood in stool 54 0.7 (1.0) 53 0.5 (0.8)
General well-being 54 0.6 (0.7) 54 0.6 (0.8)
Extra-colonic features 54 0.5 (0.6) 54 0.5 (0.6)
HBI (total) 64 5.2 (4.2) 62 5.2 (4.4)
General well-being 74 0.9 (0.8) 74 0.8 (0.8)
Abdominal pain 73 0.9 (1.0) 72 0.7 (0.9)
Number of liquid stools/day 67 2.1 (2.7) 64 2.3 (3.4)
Abdominal mass 74 0.3 (0.7) 68 0.3 (0.8)
Complications 73 1.0 (1.0) 71 1.0 (1.0)
UC: ulcerative colitis; CD: Crohn’s disease; Std: standard deviation; SHS: Short Health Scale; SCCAI: Simple Clinical Colitis Activity Index; HBI: Harvey–Bradshaw Index.
Figure 1. Bland–Altman plots of SHS for UC and CD. The full-drawn line marks the zero value on the ordinate. The dotted horizontal lines mark the mean difference
and the limits of agreement, which are defined as the mean difference plus and minus 1.96 times the standard deviation of the differences.



























The present study had strengths and limitations that need
to be considered. A strength of this study is that the patients
were familiar with SCCAI and HBI questions, as these scores
have been used in our clinic for many years. Therefore, differ-
ences in answers between paper questionnaires and touch
screens were not confounded by difficulties in understanding
the questions.
The touch screen demands an answer, and while it is pos-
sible to proceed without answering, this can only happen after
actively accepting to omit the answer. Probably for this reason,
the number of missing data was higher in the paper group
and although not statistically significantly so, this favors the
use of touch screens. We saw examples of UC patients receiv-
ing CD questionnaires and vice versa (in totally four patients)
on the paper version due to a mistake while handing out the
paper questionnaire. This did not occur with the touch screens
as the system automatically provides the questionnaires based
on the registered diagnosis of the patient.
A potential limitation of the present study is the short
time elapsed between answering questions on the touch
screen and paper version. The former study of touch screens
in rheumatology used the same approach, whereas
Hjortwang et al. and Stjernman et al. validated the SHS score
by retesting after two and four weeks, respectively.[11,12]
However, the usefulness of the latter approach in patients
with IBD is questionable, as symptoms may change over
weeks, which would result in true changes in scores and not
reflect differences in use of touch screens and paper
questionnaires.
Also, we only used the validated visual analog scale of
100 mm on touch screens, not in paper questionnaires,
because this scale had not been implemented on the paper
version in our clinic. Therefore, the validity of the results
regarding the SHS scores can be questioned. Our IBD patients
are not used to the score, which could have influenced
results and we have to consider the possibility that this score
is not fully understood by patients.
Another potential limitation was the use of the HBI sub-
score ‘Abdominal mass’, which we let the patient evaluate
without examination by a doctor. This is of course not the
optimal use of this score. Also, the HBI score is validated for
patients without previous abdominal surgery, and we used it
for all CD patients including patients with a stoma. However,
this is not likely to affect the result, since we only compared
methods of registering within the same patient.
It may be assumed that elderly patients would find the
touch screens difficult to operate, but we did not include
enough patients above 65 years to investigate this assump-
tion. Nurses and doctors reported that especially the elderly
needed assistance the first time. This was not the case for
younger patients. In our study, we saw omission of answers
or misunderstandings in more than half of the elderly partici-
pants. Further studies with age stratification are needed to
evaluate this hypothesis.
Regarding the SHS score, we found that the correlation
between the touch screen version and paper version was
comparable to previous validation studies of the SHS.[11,12]
However, it is well known that correlation is not an
appropriate measure of agreement between measurement
methods.[13]
We therefore used the Bland–Altman plots to illustrate the
agreement between the two methods (touch screen and
paper questionnaire). As the data can only attain values from
zero to 100, small averages will always be accompanied by
small differences and therefore the plots will exhibit some
degree of funnel shapeness for this data. The Bland–Altman
plots suggested some randomness in the answers with wide
limits of agreement for the SHS score. As a clinician, attention
needs to be directed to this fact when using the SHS score.
In conclusion, we found that the introduction of touch
screens instead of paper questionnaires is feasible in the IBD
outpatient clinic. Instructions are normally not needed, but
attention may be directed to the elderly, who in our experi-
ence need assistance.
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Changing Infliximab Prescription Patterns in Inflammatory Bowel 
Disease: A Population-Based Cohort Study, 1999–2014
Lone Larsen, MD,* Asbjørn Mohr Drewes, MD, PhD, DMSc,*,† Marie Christine Hede Broberg,* Jan Fallingborg, 
MD, DMSc,* Bent Ascanius Jacobsen, MD,* Thomas Bo Jensen, MD,‡ and Tine Jess, MD, DMSc†,§
Background: Long-term data on real life use of infliximab (IFX) for inflammatory bowel disease (IBD) are lacking. We studied prescription 
patterns during the first 16 years following marketing authorization.
Methods: In a population-based cohort from the North Denmark Region, all IBD patients exposed to IFX during 1999 to 2014 were identified.
Results: A total of 623 patients (210 with ulcerative colitis [UC] and 413 with Crohn’s disease [CD]) were exposed to IFX. In patients with UC, 
age at first exposure decreased by 10 months per calendar year (P < 0.05) during the study period. In patients with CD, disease duration at time of 
first IFX exposure decreased by 7 months per calendar year (P < 0.001). From 2005–2009 to 2010–2014, the proportion of IFX-exposed patients 
with pancolitis (40% vs 24%, P = 0.04) and the proportion of patients with extensive CD (P = 0.002) decreased. The mean time to discontinu-
ation of IFX remained stable in patients with CD during the study period (2.5–3.0 years) and increased from 0.34 years (2005–2009) to 1.11 years 
(2010–2015) in patients with UC (P = 0.04).
Conclusion: During the first 16 years postmarketing, age at first exposure to IFX decreased in patients with UC, whereas disease duration at 
time of first exposure decreased in patients with CD. Also, a significant change toward less extensive disease in both UC and CD patients exposed 
to IFX was observed. Treatment duration in patients with UC increased during the study period, but did not reach the more constant and longer 
duration of treatment observed in patients with CD.
Key Words:  indications, inflammatory bowel disease, infliximab, prescription patterns
Ulcerative colitis (UC) and Crohn’s disease (CD) are chronic inflammatory bowel diseases (IBDs) mainly 
affecting the gastrointestinal tract. Patients are often diag-
nosed in young adulthood, and treatment has conventionally 
included topical and oral 5-aminosalicylates and corticoster-
oids, surgery, and, in more recent decades, also thiopurines 
and other immunosuppressants. Immunotherapy with bio-
logical agents was introduced by the end of  the last millen-
nium and has been used increasingly for treatment of  IBD 
since then.1–6
As the first biological agent, infliximab (IFX) was approved 
in 1998 for treatment of CD and in 2005 for UC. Knowledge of 
the use of IFX for IBD primarily comes from clinical trials. Few 
studies are based on observational data, and their main focus is 
safety of IFX.7–21 These studies have demonstrated that IFX is 
effective and safe. Additional studies have indicated that IFX may 
improve prognosis of the disease with decreasing surgery rates.22
Few studies describe the patient population exposed to 
IFX in real life. Two studies suggest that IBD patients start-
ing IFX therapy are younger than patients treated with con-
ventional therapy,23, 24 but this may have changed with the 
gradually increasing use of IFX since its introduction to the 
market. The increasing use of IFX may also reflect treatment 
of a broader spectrum of patients with less extensive disease or 
treatment of the individual patient for a longer period of time.
We aimed to elucidate these hypotheses by assessing 
real-life use of IFX in a population-based IBD cohort fol-
lowed from 1999 to 2014 in order to describe changes in pre-
scription patterns with a focus on temporal changes in patient 
characteristics, treatment indications, and treatment duration.
MATERIALS AND METHODS
Study Population
We conducted a population-based cohort study of all IBD 
patients treated with IFX between 1999 and 2014 in the North 
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Denmark Region (583,000 inhabitants). Patients were identified 
through GASTROBIO, a web-based registry of IBD patients 
established both for research purposes and to optimize clinical 
management.25 All patients with a diagnosis of UC or CD who 
had been treated with IFX as their first biologic agent during 
1999–2014 were included. The initial dosing of IFX was 5 mg/kg 
at weeks 0, 2, and 6, and then every 8 weeks. Hereafter the interval 
could vary from 6 to 10 weeks and the dose from 5 mg/kg to occa-
sionally 10 mg/kg. No patients were on intermittent IFX dosing.
IFX has been administered to CD patients since 1999 
and to UC patients since 2005 at Aalborg University Hospital 
as the only place in the North Denmark Region to offer bio-
logical therapy. This hospital is a primary center for the popu-
lation living around the city of Aalborg, but a secondary center 
for patients living farther away who would require referral 
for evaluation and commencement of IFX. The region has a 
tradition for collecting data on all IBD patients dating back 
to 197826 and has since the introduction of IFX recorded all 
patient characteristics and treatments in the GASTROBIO 
database.25 GASTROBIO delivers data to the Danish National 
Registry for Biological Therapy in Inflammatory Bowel Disease 
(BIO-IBD). Entering data into BIO-IBD is mandatory in all 
departments in Denmark prescribing biological therapy.27
Definitions
Indications
Indications for treatment were entered by the treating 
physician into GASTROBIO and covered the following catego-
ries: “acute severe UC,” “chronically active UC,” “luminal CD,” 
and “fistulizing CD.” We defined “acute severe UC” according 
to Danish national guidelines, which are in accordance with the 
ECCO guidelines.28, 29
Disease extent 
Disease extent was determined based on endoscopic and 
radiological findings. For UC patients, disease location was 
divided into 2 groups: leftsided and pancolitis. According to 
the Montreal classification, upper gastrointestinal disease was 
used as a modifier for the rest of the locations (ileal, ileocolonic, 
and colonic disease) for CD.30
Statistical Analyses
We used mean and standard deviation for descriptive sta-
tistics of continuous variables and provided total numbers and 
percentages for the categorical variables.
For all statistical analyses, 2-sided tests were applied with 
corresponding P values, using a significance level of 5%.
To assess changes over time, linear regression was per-
formed on age at exposure and disease duration by year of first 
IFX exposure, and results were presented as a slope with 95% 
confidence intervals (CIs). A  P value for the test of 0 slope 
was also presented. To evaluate early user bias, we conducted 
sensitivity analyses removing the years 1999–2003. This did not 
apply to UC patients in whom IFX was first used from year 
2005, when clinicians were experienced in using the drug for 
CD. For the categorical variables “indications” and “disease 
extent,” we assessed temporal changes by comparing the 2 time 
periods 2005–2009 and 2010–2014 for UC and 1999–2009 and 
2010–2014 for CD using the χ2 test.
Likewise, time to discontinuation was analyzed using 
Kaplan-Meier curves, and the differences between the peri-
ods 2005–2009 and 2010–2014 for UC and 1999–2009 and 
2010–2014 for CD were compared using the log rank test. In 
order to further qualify the time to discontinuation analyses, 
we performed Cox regression analysis. Results were expressed 
as hazard ratios (HRs) with 95% CIs.
Analyses were performed using Stata (Stata/IC 12.1 for 
Windows, www.stata.com).
ETHICAL CONSIDERATIONS
The study was approved by the Danish Board of Health 




From 1999 to 2014, 717 IBD patients received biological 
therapy. Of these, 94 patients (13.1%) were excluded: 8 (1.1%) 
due to a diagnosis of “IBD unclassified,” 2 (0.3%) did not have 
IBD, 37 (5.2%) were treated with a different biological agent as 
their first biological treatment, and 47 (6.6%) had started treat-
ment at a hospital outside the region. This left 623 patients (210 
with UC and 413 with CD) exposed to IFX as their first bio-
logical agent available for analyses. Ninety-five (15%) of these 
patients (33 UC and 62 CD) were referred from a different hos-
pital in the region for biological treatment. Of these, 35 patients 
(5 UC and 30 CD) were referred during years 1999–2009, and 
60 patients (28 UC and 32 CD) during the years 2010–2014. 
Baseline characteristics are shown in Table 1. Age distribution 
at time of diagnosis is shown in Fig. 1.
Patient Age and Disease Duration
Age at exposure
Overall, the mean age at first exposure to IFX was 
37.0  years for UC patients and 34.5  years for CD patients. 
During years 2005–2014, the age at first IFX exposure decreased 
by approximately 10 months or 0.8 years per calendar year (95% 
CI, –1.58 to –0.03; P < 0.05) in patients with UC. In the overall 
period (1999–2014), age at first exposure to IFX in patients 
with CD did not change significantly (–0.12  years/calendar 
year; 95% CI, –0.49 to 0.26; P = 0.53). The sensitivity analysis 
for CD (2004–2014 only) was insignificant as well (–0.17 years/
calendar year; 95% CI, –0.67 to 0.34; P = 0.52).
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Disease duration
Overall, the mean time from IBD diagnosis to first 
IFX exposure was 6.5 years in both UC and CD patients and 
6.0 years in CD patients when analyzing years 2004–2014 only. 
Time to first IFX exposure did not change during the study 
period among patients with UC (reduction of 0.26 years/cal-
endar year; 95% CI, –0.78 to 0.26; P = 0.30), while in patients 
with CD, a decrease in time to first exposure of approximately 
TABLE 1. Baseline Characteristics of a Population-Based Cohort of Patients With Inflammatory Bowel Disease 
Exposed to Infliximab (1999–2014)
Ulcerative Colitis Crohn’s Disease Total
Patients, No. (%) 210 413 623
 Male 108 (51) 170 (41) 278 (45)
 Female 102 (49) 243 (59) 345 (55)
Age at diagnosis, No. (%) 210 413 623
 Mean (SD), y 30.5 (14.9) 28.1 (12.9) 28.9 (13.6)
Age at IFX, No. (%) 209 412 621
 Mean (SD), y 37.0 (15.8) 34.5 (14.3) 35.4 (14.8)
BMI, No. (%) 150 315 465
 Mean (SD), kg/m2 25.9 (5.5) 24.3 (5.4) 24.8 (5.5)
Smoker, No. (%) 207 397 604
 Yes 20 (9.7) 141 (35.5) 161 (26.7)
 Previous 65 (31.4) 80 (20.2) 145 (24.0)
 Never 104 (50.2) 160 (40.3) 264 (43.7)
 Unknown 18 (8.7) 16 (4.0) 34 (5.6)
IBD family history, No. (%) 181 372 553
 Yes 28 (15.5) 64 (17.2) 92 (16.6)
 No 153 (84.5) 308 (82.8) 461 (83.4)
Indication for IFX, No. (%) 182 257 439
 Severe acute UC 58 (31.9)
 Chronically active UC 124 (68.1)
 Fistulizing CD 58 (22.6)
 Luminal CD 199 (77.4)
FIGURE 1. Age distribution at time of diagnosis in patients with inflammatory bowel disease later treated with infliximab.
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7 months or 0.6 years per calendar year (95% CI, –0.84% to 
–0.33%; P < 0.001) was observed. This was also the case when 
studying years 2004–2014 only (a decrease of approximately 
5 months or 0.41 years per calendar year; 95% CI, –0.72% to 
–0.01%; P < 0.03).
Indications
The indication for starting treatment with IFX was 
known for 93% of UC patients. Of these, 32% had severe acute 
UC and 68% had chronically active UC. The indication was 
known for 62% of CD patients, with 23% having fistulizing dis-
ease and 77% having luminal disease. Although the absolute 
number of patients receiving IFX during the period increased, 
the distribution of indications did not change significantly from 
before 2010 to 2010–2014, when comparing proportions of se-
vere acute and chronically active disease in UC (32% vs 68% in 
both periods, P = 1.00) and fistulizing and luminal disease in 
CD (21% and 79% before 2010 vs 24% and 76% in 2010–2014, 
P = 0.66).
Disease Extent
Data on disease extent were available for 149 (71%) of 
UC patients and 284 (67%) of CD patients. Disease extent at 
diagnosis in patients exposed to IFX in the first vs the second 
calendar period is shown in Fig.  2 for UC and in Fig.  3 for 
CD. The proportion of UC patients with pancolitis was higher 
in the group initiating IFX treatment between 2005 and 2009 
(40%) than in patients initiating treatment between 2010 and 
2014 (24%) (P  =  0.04) (Fig.  3). In the latter period, patients 
were more likely to have left-sided colitis. In patients with CD, 
we observed an increase in the proportion of patients with iso-
lated ileal disease exposed to IFX from the period 2005–2009 
(4%) to the period 2010–2014 (13%), while the proportion of 
patients with more extensive disease decreased (P  =  0.006) 
(Fig. 3).
Duration of Treatment
In patients with UC, the median interval from start of 
treatment with IFX to discontinuation increased significantly 
from 0.34 years in patients exposed to IFX during 2005–2009 
to 1.11 years in patients starting treatment during 2010–2014, 
as reflected by an HR of 1.42 (95% CI, 1.02 to 1.98; P = 0.04) 
(Fig. 4).
In patients with CD, the median duration of IFX treat-
ment was almost 3 years in both 2005–2009 (2.57 years) and 
2010–2014 (2.96 years), and, accordingly, our regression ana-
lysis showed an HR of 0.93 (95% CI, 0.71 to 1.22; P = 0.60) 
(Fig. 5).
Causes for discontinuation are shown in Table  2. 
Remission was the cause for discontinuation in slightly more UC 
(41.8%) than CD (31.8%) patients (P = 0.05). This was also the 
case for poor response (35.3% in UC vs 23.4% in CD, P = 0.01). 
Adverse events were an almost equally common course in UC 
patients (5.2%) and CD patients (11.3%, P = 0.07), whereas sur-
gery was the cause in only 6.7% of CD patients vs 19.6% of UC 
patients (P < 0.001).
DISCUSSION
In the present population-based cohort study, we de-
scribe real-life use of IFX in a geographically well-defined IBD 
population observed from the beginning of the biological era 
and 16 years ahead. Our data revealed that IFX was introduced 
at an increasingly younger age in UC during the observation 
period and that the interval from diagnosis to IFX exposure be-
came shorter in CD. Further, the proportion of patients treated 
for extensive disease decreased during the period in both CD 
and UC, whereas indications (acute vs chronic disease in UC 
and fistulizing vs luminal in CD) did not change over time. 
Of note, time to discontinuation of treatment remained stable 
in patients with CD during the study period, but it increased 
in patients with UC, without reaching the level observed in 
patients with CD, however.
FIGURE 2. Disease extent at time of diagnosis of ulcerative colitis by 
period of first infliximab prescription (n = 147).
FIGURE 3. Disease extent at time of diagnosis of Crohn’s disease by 
period of first infliximab prescription (n = 284).
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The present study has several strengths. First, data were 
collected in 1 center with the same core of physicians through-
out the period. Second, the population is geographically well 
defined and covers 583,000 citizens, which allows the study of 
the real-life use of the first available biological agent, IFX, in an 
unselected population during the first 16 years postmarketing. 
This is an incomparably long study period. Third, our study 
reflects the daily life of a large outpatient clinic offering bio-
logical therapy. Representing a real-life setting, which is less 
controlled than phase 3 drug testing, our population enables 
the study of the true and broad spectrum of patients with no 
selection related to age, previous surgery, or other common 
exclusion criteria.
The study also has potential limitations, which need to 
be considered. First, while Aalborg University Hospital is a 
primary center for the part of  the population in the North 
Denmark Region centered on the city of  Aalborg, it is also 
a secondary center for patients living farther away in the 
region. These patients have a different primary center that 
does not offer biological therapy, and therefore, there could 
be a delay in referring these patients to treatment. This could 
not be taken into account in the present study, but it hardly 
affects results, as there has been no change in the organiza-
tion of  health care during the study period. Second, there is 
no knowledge on how the missing data are distributed in this 
study. Initially, GASTROBIO did not register disease extent 
FIGURE 4. Time from first infliximab prescription to discontinuation in a population-based cohort of patients with ulcerative colitis (n = 208).
FIGURE 5. Time from first infliximab prescription to discontinuation in a population-based cohort of patients with Crohn’s disease (n = 413).
Downloaded from https://academic.oup.com/ibdjournal/article-abstract/24/2/433/4816940
by Medicinsk Bibliotek, Aalborg Sygehus SYD user
on 06 March 2018
 Inflamm Bowel Dis • Volume 24, Number 2, February 2018
438
Larsen et al
at diagnosis if  the index endoscopy was performed at a differ-
ent hospital. Although we have tried to handle this through 
manual scrutiny of  patient files, this explains the missing data 
on disease extent in a subpart of  the cohort. Third, it may be 
seen as a limitation that disease extent subject to analysis in 
the present study corresponds to the extent at time of  diag-
nosis rather than at time of  exposure. Fourth, the number of 
hospitalizations during the study period was not recorded 
systematically, so any change in hospitalization pattern could 
not be assessed. Fifth, the categorization into remission or 
poor response was based on physicians ticking a box when 
deciding to discontinue treatment for the patient. Finally, in 
relation to investigative practice, we know that the use of  mag-
netic resonance enterography (MRE) has increased during the 
study period, although the magnitude of  such use was not 
measured. The increasing use of  MRE is expected to result in 
increased identification of  cases with mild disease, hence not 
explaining the increasing use of  biological therapy during the 
study period.
We observed that age at first IFX exposure decreased in 
patients with UC during the study period, whereas this was 
not the case in CD. On the other hand, patients with CD were 
exposed to IFX after increasingly shorter disease duration dur-
ing the study period, whereas a similar finding in UC did not 
reach statistical significance. As a possible accumulation of 
patients ready for IFX treatment in the beginning of the study 
period was not apparent, our observations seem to reflect a 
genuine change in prescription patterns during the period.
We observed no change in indications for treatment, in 
terms of acute severe vs chronically active UC and luminal vs 
fistulizing CD during the study period, which is in line with 
the fact that there has been no change in recommendations for 
treatment of the subgroups of the diseases. However, patients 
tended to be treated for less extensive disease in the last part 
of the study period. This was the case in both UC and CD 
and appears to reflect a change in prescription patterns toward 
treatment with IFX at an earlier stage of disease in patients 
with less extensive disease.
Also, time to discontinuation changed over time, at least 
in patients with UC, with increasing treatment duration during 
the observation period. Desai et al.24 showed that patients older 
than 60 years of age were more likely to discontinue therapy 
within the first year than younger patients. As our population 
of UC patients was increasingly younger at first exposure, they 
may have been less likely to discontinue therapy. However, the 
increasing time to discontinuation may also reflect a tendency 
in clinical practice toward 1-year continuation of IFX treat-
ment in patients with UC rather than just induction therapy. 
Overall, we observed several reasons for discontinuation of IFX 
treatment, remission being the cause in 30%–40% of patients, 
hence resembling remission rates reported by Schnitzler et al. in 
2009 from a single-center cohort study of 614 patients.8 It has 
been speculated that decreasing surgery rates in patients with 
UC during the same period relate to IFX treatment, but this 
remains uncertain.22
In patients with CD, the mean treatment duration was 
more stable during the study period and longer than the mean 
time in patients with UC (around 3  years vs 1  year), which 
remains unexplained. In contrast to our finding of  50% of CD 
patients discontinuing treatment after 3 years, Pressman et al.23 
TABLE  2. Causes for Discontinuation of Infliximab Treatment in a Population-Based Cohort of Patients With 







No. (%) 153 (100) 239 (100) 392 (100)
Remission 64 (41.8) 76 (31.8) 0.05 140 (35.7)
Poor response 54 (35.3) 56 (23.4) 0.01 110 (28.1)
Adverse events 8 (5.2) 27 (11.3) 0.07 25 (6.4)
Cancer 0 (0.0) 1 (0.4) 1.00 1 (0.3)
Change of hospital 1 (0.7) 4 (1.7) 0.65 5 (1.3)
Infection 1 (0.7) 0 (0.0) 0.39 1 (0.3)
Surgery 30 (19.6) 16 (6.7) 0.000 46 (11.7)
Clinical trial participation 0 (0.0) 2 (0.8) 0.52 2 (0.5)
Lost to follow-up 1 (0.7) 2 (0.8) 1.00 3 (0.8)
Deceased 0 (0.0) 4 (1.7) 0.16 4 (1.1)
Other 14 (9.2) 40 (16.7) 0.04 54 (13.8)
Unknown 4 (2.6) 11 (4.6) 0.42 15 (3.8)
P values reflect comparison of patients with ulcerative colitis and Crohn’s disease by χ2 test for each cause of discontinuation. The same patient can appear in more than 1 cat-
egory due to competing causes of discontinuation.
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reported that 80% discontinue after 3 years. While Pressman 
and colleagues’ study was conducted during the earlier part 
of  our study period, we observed a stable time to discontinu-
ation during the entire period. This may partly be due to a 
lower frequency of  adverse events in our study as compared 
with several10, 15, 20 but not all previous studies.21 The lower fre-
quency may be explained by better dose adjustment, a single 
and experienced center serving a whole region, or other yet 
unknown factors. Overall, the number of  real-life long-term 
studies on use of  biologics in IBD is limited, which minimizes 
the potential for comparison of  the present findings with exist-
ing literature.
In conclusion, our unselected cohort study revealed a 
decrease in age of UC patients and a decrease in duration of 
CD at the time of first IFX exposure during the initial 16 years 
of observation postmarketing. Further, we observed a signifi-
cant change toward less extensive disease in both CD and UC 
patients exposed to IFX and an increasing time to discontinu-
ation in patients with UC in recent years. This indicates that 
prescription patterns have changed since IFX was introduced 
to the market. Better knowledge of and experience in using bio-
logical therapies, less hesitation in prescribing IFX to a broader 
range of patients, and reduction in costs of IFX may to some 
extent explain our findings. However, determining the causes of 
these changes requires further studies.
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Premedication with corticosteroids does not impact
the pharmacokinetics of infliximab in inflammatory
bowel disease irrespective of azathioprine
cotreatment
Lone Larsena, Tine Jessc,d, Asbjørn M. Drewesa,c, Anders Digee, Jan Fallingborga, Bent A. Jacobsena,
Bitten Aagaardb and Jørgen Agnholte
Objective Loss of infliximab (IFX) effect is a clinical challenge in the management of patients with Crohn’s disease (CD), but this
can potentially be reduced with azathioprine (AZA) or with corticosteroids (CS). We aimed to study whether CS premedication
with or without cotreatment with AZA could reduce antibody formation and affect the IFX elimination rate.
Patients and methods A cross-sectional observational study was conducted at two centers with CD patients receiving
maintenance IFX therapy for 12–18 months. In addition to IFX, patients received either CS premedication or not, with or without
concominant AZA.
Results Fifty-seven patients were included in the study. Thirty-one patients received premedication with CSs, and 11 (35.5%) of
these also received AZA, whereas this was the case for 22 of 26 (84.6%) patients in the non-CS group. No difference in IFX
trough level (P=0.10) or halftime elimination (P= 0.31) was observed with or without CS premedication. Concomitant AZA was
associated with significantly longer mean half-life of IFX (P=0.04). Total IFX antibody concentrations were 15.8 and 12.9 with and
without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those
receiving AZA (P=0.004). Premedication with CS did not have any effect on the frequency of antibody formation (P= 0.28).
Conclusion In patients with CD and in maintenance IFX therapy, premedication with CS did not influence antibody formation,
IFX trough levels or IFX halftime elimination, irrespective of concomitant AZA use. However, the use of AZA was associated with
higher IFX trough levels and lower total IFX antibody concentrations. Eur J Gastroenterol Hepatol 00:000–000
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
Infliximab (IFX) is an effective treatment for Crohn’s dis-
ease (CD). IFX is a chimeric tumour necrosis factor (TNF)-
α antibody consisting of 25% nonhuman (murine) protein,
which in patients has been shown to cause the formation
of IFX antibodies in up to 30% of patients [1]. This can
lead to a reduced/or loss of anti-inflammatory effect [2–6].
Several studies have demonstrated that combined ther-
apy with IFX and azathioprine (AZA) reduces antibody
formation [3,7], but it has been questioned whether pre-
infusion premedication with corticosteroids (CS) can
reduce the formation of IFX antibodies. Hence, in a ran-
domized placebo-controlled trial in patients with CD,
Farrell et al. [8] showed that 200mg of hydrocortisone on
the day of IFX infusion led to significantly less antibody
formation towards IFX.
Studies conducted within the field of rheumatology
have shown diverging conclusions [9–19], and a role for
prophylactic CS in IFX therapy has so far not been
established.
The purpose of this study was to investigate whether CS
premedication with or without AZA comedication during
IFX therapy could affect the frequency of IFX antibody
formation, trough levels and the elimination rate of IFX.
Patients and methods
Study population
Patients with CD who received IFX maintenance therapy
were included at two Danish centers between 2015 and
2017. All patients had a well-established diagnosis of CD
and received IFX therapy for 12–18 months. All patients
were naive to biological therapy at the initiation of the
treatment and were selected as a trans-sectional cohort to
participate consecutively in the study. The inclusion cri-
teria were as follows: CD, age above 18 years, and
maintenance IFX treatment for 12–18 months.
Disease extent, disease behavior, prior history of sur-
gery, family history, and smoking habits were registered.
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Premedication
The premedication with CS consisted of 40mg of pre-
dnisolone orally on the day before IFX therapy and 40mg
of methylprednisolone (SoluMedrol, Pfizer, Denmark)
intravenously on the day of IFX infusion.
Comedication
All patients on AZA therapy had been on a stable dose for
at least 3 months at a dose of 1.5–2.5 mg/kg.
Samples
After inclusion of a patient, blood samples were obtained
at the next scheduled IFX infusion for IFX concentrations
before IFX infusion (trough level), 1 h after IFX infusion
ended (peak-level) and 1 week after IFX infusion. IFX
antibody concentration was measured before IFX infusion.
Laboratory tests
Infliximab concentration
A two-step immunoassay based on ELISA technique
measured IFX concentration in human serum. All samples
were tested as duplicates. The result was determined by the
development of chemiluminescence in the terminal phase.
The following procedure was done on blood samples
obtained just before IFX infusion, time=0: TNF-α (1 mg/
ml) (Tebu-Bio., Roskilde, Denmark) coated – and satu-
rated with PBS containing 1% bovine serum albumin.
Microtiter 96-well plates (Nunc C8 white MaxiSorp;
Fisher Scientific Labosi, Elancourt, France) were washed
four times with PBS tween (PBS pH 7.2 + 0.05% Tween
20) before 100 µl diluted (1 : 100/1 : 800) patient sample
was added. The plates were incubated 2 h at 37°C, fol-
lowed by four times wash with PBS Tween. A conjungate,
Fc-specific alkaline phosphatase (Sigma-Aldrich, Saint-
Quetin-Fallavier, France) linked goat antihuman-IgG was
added, and the plates were left for 1 h shaking incubation
at room temperature. Once more, the plates were washed
four times with PBS Tween before two times wash in assay
buffer (Applied BioSystems, Foster City, California, USA).
Substrate chemiluminescent alkaline phosphatase (Applied
BioSystems) 100 µl was added and incubated for 10min at
room temperature in darkness. The chemiluminiscence reac-
tion (FluoStar Optima with MARS data analysis software;
Ramcon, Birkeroed, Denmark) was read as relative units of
light. The relative units of light and the concentration of IFX
are proportional. The limit of detection was 0.5 μg/ml.
The same procedure, as described above, was used for
the postinfusion samples, but patient samples were further
diluted to 1 : 5000/1 : 10 000/1 : 20 000.
Total human antibodies against infliximab
Blood samples before infusion: IDKmonitor (Immundiagnostik
AG, Stubenwald-Allee, Bensheim, Germany) IFX total ADA
ELISA is a CE-branded test based on the ELISA principle. The
test determined human antibodies against TNF-α blocker IFX
in the presence of IFX in plasma, that is, a drug-tolerant assay.
‘Total’ ADA refers to the measurement of both free and bound
antibodies against IFX.
Statistical analyses
Linear regression was used to test for differences in trough
values, peak values and t1/2 of IFX concentrations, and
trough values of IFX antibody concentrations between the
±CS premedication groups. Furthermore, we tested for
possible interaction between the ±CS groups and ± con-
comitant AZA treatment.
We applied the logarithmic transformation to the IFX
concentrations and antibody concentrations in order to
obtain normal distributed data and therefore geometric
means and coefficients of variation were reported. This
was not the case for IFX t1/2, as these data were normal
distributed. For IFX t1/2, means and standard deviations
were reported.
The assumption of normality was checked by inspection
of QQ-plots.
Ethical considerations
All patients gave informed consent. The study was approved
by the Regional Ethics Committee (N-20140003) as well as
by the Danish Data Protection Agency (2008-58-0028).
Results
Patient characteristics
From 2015 to 2017, 57 CD patients were included in the
study. Two patients failed to show up for the one-week
blood sampling. Patient characteristics are shown in
Table 1. Twenty-two (84.6%) −CS patients were on
concomitant immunomodulatory therapy, while this was
the case for 11 (35.5%) +CS patients.
Overall, 59.6% were female individuals. The two
patient groups were comparable (Table 1).
Infliximab concentrations
The geometric mean trough levels were 5.1 and 7.3 μg/ml for
−CS and +CS patients, respectively (P=0.10). Likewise,
there was no difference in the geometric mean peak con-
centrations: 263.8 μg/ml for −CS and 285.3 μg/ml for +CS
patients (P=0.48), or the 1-week-after concentrations:
104.4 μg/ml for −CS and 114.0 μg/ml for +CS patients
(P=0.63). Box plots of the different concentrations are
shown in Fig. 1. In patients with concomitant AZA, the
trough level was significantly higher (P=0.02, Table 2).
Infliximab elimination rate
The mean half-life of IFX was 10.5 days in both groups
(minimal 5.4 and 5.4 days and maximal 19.1 and
17.5 days for +CS and −CS, respectively). There was no
difference between the two administration methods
(P=0.31). For individual elimination curves (Fig. 2).
However, concomitant AZA was associated with sig-
nificantly longer mean half-life of IFX (P=0.04; Table 2).
Infliximab antibody concentrations
The mean total IFX antibody concentration was 10.0
AU/ml in +CS patients and 6.7 AU/ml in −CS patients
(P=0.28). Patients without AZA therapy had a sig-
nificantly higher IFX antibody concentration (P= 0.004;
Table 2).
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Twenty-two (38.6%) patients had detectable total IFX
antibodies (cutoff>10 AU/ml). Of them, 15 (68.2%) were
in the +CS group, and seven (31.8%) were in the
−CS group.
Discussion
In this cross-sectional observational study of patients with
CD receiving IFX with or without comedication with AZA
for at least a year, we evaluated the effect of premedication
with CS.
Our data did not demonstrate any effect of CS pre-
medication with regard to the frequency of IFX antibody
formation, trough levels, and the elimination rate of IFX,
whereas concomitant AZA therapy reduced the
concentration of IFX antibodies. Besides, we found sig-
nificantly higher trough values of IFX and longer IFX half-
life in patients who received AZA therapy.
The question is relevant, as antibody formation towards
anti-TNF biologics and loss of effect represent a therapeutic
challenge in the clinical management of inflammatory bowel
disease patients. Therefore, it was important to investigate
Table 1. Patient characteristics
Treatment (N) −Corticosteroid (26) +Corticosteroid (31) Total (57)
Female individuals [n (%)] 16 (61.5) 18 (58.1) 34 (59.6)
Age at time of study [mean (SD)] 33.3 (13.8) 31.6 (11.8) 32.4 (12.7)
Weight [mean (SD)] (kg) 75 (13.5) 80.5 (21.5) 78.0 (18.4)
Height [mean (SD)] (cm) 171.6 (9.6) 172.8 (8.9) 172.4 (9.1)
Smoking at diagnosis [N (%)] 5 (20.8) 4 (12.9) 9 (16.4)
Family history of inflammatory bowel disease [N (%)] 5 (21.7) 4 (12.9) 9 (16.7)
Concomitant medication [N (%)] 22 (84.6) 14 (45.2) 36 (63.2)
Azathioprine 22 (84.6) 11 (35.5) 33 (57.9)
6-Mercaptopurine 0 (0) 3 (9.7) 3 (5.3)
Previous surgery [N (%)] 5 (19.2) 8 (27.6) 13 (23.6)
Disease extent [N (%)] 26 (100) 31 (100) 57 (100)
Colon 8 (30.8) 19 (61.3) 27 (47.4)
Ileocolonic 15 (57.7) 9 (29.0) 24 (35.1)
Small bowel 2 (7.7) 3 (9.7) 5 (8.8)
Upper gastrointestinal 1 (3.9) 0 (0) 1 (1.7)
Disease behaviour [N (%)] 26 (100) 31 (100) 57 (100)
Nonstricturing, nonfistulizing 16 (61.5) 19 (61.3) 35 (61.4)
Fistulizing, nonstricturing 5 (19.2) 11 (35.5) 16 (28.1)
Stricturing, nonfistulizing 5 (19.2) 1 (3.2) 6 (10.5)
Infliximab interval, 5 mg/kg every 4-10 weeks
[mean (minimum–maximum)]
7.65 (6–10) 7.23 (4–10) 7.42 (4–10)
Fig. 1. Log concentrations of infliximab.
Table 2. Distribution of infliximab trough levels, half-life and total infliximab antibody concentrations according to premedication
−Corticosteroid +Corticosteroid
Treatment (N) Azathioprine (22) No AZA (4) Azathioprine (11) No AZA (20)
Trough levels [geometric mean (CV)] (μg/ml)* 5.97 (1.27) 2.19 (0.76) 9.14 (1.42) 6.44 (2.55)
Half-life [mean (SD)] (days)** 10.8 (3.2) 8.7 (0.6) 11.7 (2.5) 9.9 (3.2)
Total IFX antibody concentrations [geometric mean (CV)] (AU/ml)*** 6.1 (1.58) 12.9 (0.76) 4.3 (1.42) 15.8 (2.55)
AZA, azathioprine; CV, coefficient of variation; IFX, infliximab.
*P=0.023, trough values higher with AZA.
**P=0.04, half-life longer with AZA.
***P=0.004, IFX antibody concentrations lower with AZA.
Fig. 2. Elimination of infliximab by each individual.
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the theoretical presumption that premedication with CS
would diminish the formation of IFX antibodies. Another
study has addressed the question of premedication with CS
as a modulator of immunological reactions.
In a randomized placebo-controlled trial in patients
with CD, Farrell et al. [8] showed that 200mg of hydro-
cortisone on the day of IFX infusion led to significantly less
antibody formation towards IFX. However, it did not
eliminate the antibody formation or infusion reactions. In
contrast, in a recent retrospective study from Gold et al.
[20], premedication use was not effective in reducing acute
IFX reactions.
The findings concerning the effect of AZA are in
accordance with the SONIC trial and are also in accor-
dance with the results described by Fasanmade and col-
leagues [21,22].
This study has several strengths. First, to our knowl-
edge, this is the first study evaluating steroid premedication
after 12–18 months’ IFX treatment in a prospective man-
ner. Second, the study is standardized in the timing of the
blood sampling.
The study also has potential limitations, which should
be considered. First, the small sample size makes it possible
that a small effect of CS premedication might have been
overlooked. However, the results did not even indicate a
trend towards an effect of CS premedication. Second, the
patients in this study received maintenance IFX therapy for
a minimum of 12 months, which might cause a selection
bias. Hence, patients who were able to participate in the
study were able to tolerate the treatment (cessation of IFX
treatment due to side effects or intolerance was not
registered).
Conclusion
This study did not find any effect of CS premedication on
TNF-antibody production irrespective of concomitant
AZA treatment. However, we did observe a positive effect
of AZA with regard to a reduced production of TNF
antibodies. Thus, this study strengthens the argumentation
for comedication with AZA in patients on IFX therapy,
but it does not support the use of premedication with CS.
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